From the Journals

Low-dose steroids may not increase cardiovascular risk in rheumatoid arthritis


 

FROM ANNALS OF THE RHEUMATIC DISEASES

Long-term glucocorticoid use discouraged

Daily doses of less than 5 mg were not associated with higher MACE risk, but more research is necessary to understand whether these low doses are clinically efficacious, Dr. Tam said. “The study results suggest that a very-low-dose GC (less than 5 mg prednisolone daily) may be cardiovascular risk–neutral. However, further evaluation is needed to determine whether this dose is therapeutic. Other potential side effects, such as bone loss, increased infection risk, dyslipidemia, and hyperglycemia, should also be considered.”

Both the American College of Rheumatology and the European Alliance of Associations for Rheumatology acknowledge that short-term GCs may be necessary for some RA patients, but they emphasize using the smallest necessary dose for the shortest period possible because of the known toxicity of GCs.

“We recommend stopping GCs as soon as it is clinically feasible, in line with previous recommendations, until these issues are investigated further,” Dr. Tam added.

Dr. Bartels agreed that long-term use of GCs should be avoided if possible, even at lower doses, because although CV risk may be less of an issue, studies have shown an increased risk for infection even at GC doses of less than 5 mg a day.

How might risk increase with dose?

While the study showed a distinct difference in risk with doses of prednisolone higher and lower than 5 mg, more information on how risk increases with dose could be useful, said Beth Wallace, MD, an assistant professor in internal medicine at the University of Michigan, Ann Arbor, and a staff rheumatologist at the VA Ann Arbor Healthcare Center. She was also unaffiliated with the research. “If someone is on 5-10 mg ... how much better is that than being on 10-20 mg or being on 20-30 mg?” she asked. While these study findings are “very important,” she said, it would be useful to know the risk associated with 7.5 mg vs. a higher dose.

Dr. Beth Wallace, assistant professor in internal medicine at the University of Michigan and a staff rheumatologist at the VA Ann Arbor Healthcare Center University of Michigan

Dr. Beth Wallace

Dr. Wallace also noted that the study population was generally healthy, with lower rates of diabetes, high blood pressure, and high cholesterol, compared with American patients. The mean disease duration at baseline was around 8 months, and only 3% were taking biologics. Performing this type of analysis in a U.S. or global cohort would be useful to see whether risk estimates are similar, Dr. Bartels said.

But even in this relatively healthy population in Hong Kong, “taking more than 5 mg of prednisolone doubles the risk of cardiovascular disease,” Dr. Wallace added. This is important for clinicians to know, especially if they are more cautious about prescribing steroids to older or sicker patients but are “using [the drugs] a little more indiscriminately in younger people and healthier people.”

The study did not receive outside funding. Dr. Tam and Dr. Bartels report no relevant financial relationships. Dr. Wallace has received a grant from the Department of Veterans Affairs Administration to study steroid tapering in RA.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

ILD risk elevated in RA, PsA after starting biologic or targeted synthetic DMARDs
Federal Practitioner
Studies reveal nuances in efficacy, MACE risk between JAKi and TNFi
Federal Practitioner
Is ChatGPT a friend or foe of medical publishing?
Federal Practitioner
Why not both? Dual biologics for treatment-resistant RA and PsA
Federal Practitioner
High-intensity interval training has sustainable effects in patients with inflammatory arthritis
Federal Practitioner
RA and demyelinating disease: No consistent link to TNFi
Federal Practitioner
AI efforts make strides in predicting progression to RA
Federal Practitioner
After Yusimry’s steep discount, little clarity on future adalimumab biosimilar pricing
Federal Practitioner
Methotrexate does not impair sperm quality, small study finds
Federal Practitioner
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
Federal Practitioner